Management of glucocorticoid-induced osteoporosis

Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899 Díez-Pérez A, Hooven FH, Adachi JD et al (2011) Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 49:493–498 Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787 Natsui K, Tanaka K, Suda M et al (2006) High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int 17:105–108 Adachi JD, Saag KG, Delmas PD et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211 Cohen S, Levy RM, Keller M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309–2318 Reid DM, Devogelaer JP, Saag K et al (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253–1263 van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000 van Staa TP, Geusens P, Pols HA et al (2005) A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 98:191–198 Waljee AK, Rogers MA, Lin P et al (2017) Short term use of oral corticosteroids and related harms among adults in the United States: population-based cohort study. BMJ 357:j1415 Amiche MA, Abtahi S, Driessen JHM et al (2018) Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. Arch Osteoporos 13:30 De Vries F, Bracke M, Leufkens HG et al (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208–214 Schett G, Saag KG, Bijlsma JW (2010) From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis 69:1415–1419 Best JH, Kong AM, Lenhart GM et al (2018) Association between glucocorticoid exposure and health care expenditures for potential glucocorticoid-related adverse events in patients with rheumatoid arthritis. J Rheumatol 45:320–328 Buttgereit F, Straub RH, Wehling M et al (2004) Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 50:3408–3417 O’Brien CA, Jia D, Plotkin LI et al (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:835–841 Hildebrandt S, Baschant U, Thiele S et al (2018) Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo. Sci Rep 8:8711 Ohlsson C, Nilsson KH, Henning P et al (2018) WNT16 overexpression partly protects against glucocorticoid-induced bone loss. Am J Physiol Endocrinol Metab 314:E597–E604 Ohnaka K, Tanabe M, Kawate H et al (2005) Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 329:177–181 Wang FS, Ko JY, Yeh DW et al (2008) Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 149:1793–1801 Kato T, Khanh VC, Sato K et al (2018) Elevated expression of Dkk-1 by glucocorticoid treatment impairs bone regenerative capacity of adipose tissue-derived mesenchymal stem cells. Stem Cells Dev 27:85–99 Butler JS, Queally JM, Devitt BM et al (2010) Silencing Dkk1 expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation. BMC Musculoskelet Disord 11:210 Cárcamo-Orive I, Gaztelumendi A, Delgado J et al (2010) Regulation of human bone marrow stromal cell proliferation and differentiation capacity by glucocorticoid receptor and AP-1 crosstalk. J Bone Miner Res 25:2115–2125 Hofbauer LC, Gon F, Riggs BL et al (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382–4389 Pereira RMR, Delany AM, Durant D et al (2002) Cortisol regulates the expression of notch in osteoblasts. J Cell Biochem 85:252–258 Zanotti S, Yu J, Adhikari S et al (2018) Glucocorticoids inhibit notch target gene expression in osteoblasts. J Cell Biochem 119:6016–6023 Zhang S, Liu Y, Liang Q (2018) Low-dose dexamethasone affects osteoblast viability by inducing autophagy via intracellular ROS. Mol Med Rep 17:4307–4316 Weinstein RS, Hogan EA, Borelli MJ et al (2017) The pathophysiological sequence of glucocorticoid-induced osteonecrosis of the femoral head in male mice. Endocrinology 158:3817–3831 Schakman O, Kalista S, Barbe C et al (2013) Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 45:2163–2172 Sculz P, Beck TJ, Marchand F et al (2005) Low skeletal muscle mass is associated with poor structural parameters of bone and impaired balance in elderly men—the MINOS study. J Bone Miner Res 20:721–729 Weinstein RS (2011) Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 365:62–70 Canalis E, Mazziotti G, Giustina A et al (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328 Hu K, Adachi JD (2019) Glucocorticoid induced osteoporosis. Expert Rev Endocrinol Metabol 14:259–266 Lane NE (2019) Glucocorticoid-induced osteoporosis: new insights into the pathophysiology and treatments. Curr Osteoporos Rep 17:1–7 Compston J (2018) Glucocorticoid-induced osteoporosis: an update. Endocrine 61:7–16 Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int 30:1145–1156 Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257–2276 Buckley L, Guyatt G, Fink HA et al (2017) 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 69:1521–1537 Shuhart CR, Yeap SS, Anderson PA et al (2019) Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. J Clin Densitom 22:453–471 Iacopo C, Alberto F, Daniela M et al (2020) Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis. Expert Rev Endocrinol Metabol 15:283–298 Silva BC, Leslie WD, Resch H et al (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 29:518–530 Dubrovsky AM, Maricic M, Lane NE (2020) Glucocorticoid-induced osteoporosis. In: Leaer BZ, Wein MN (eds) Osteoporosis: pathophysiology and clinical management, 3rd edn. Humana, Cham, pp 407–418 Leib ES, Winzenrieth R (2016) Bone status in glucocorticoid-treated men and women. Osteoporos Int 27:39–48 Florez H, Hernández-Rodríguez J, Muxi A et al (2020) Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. Rheumatology 59:1574–1580 Saag KG, Agnusdei D, Hans D et al (2016) Trabecular bone score in patients with chronic glucocorticoid therapy-induced osteoporosis treated with alendronate or teriparatide. Arthritis Rheumatol 68:2122–2128 Leib ES, Saag KG, Adachi JD et al (2011) Official positions for FRAX® clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX® of the 10-year risk of fracture: from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 14:212–219 Güler-Yüksel M, Hoes JN, Bultink IE et al (2018) Glucocorticoids, inflammation and bone. Calcif Tissue Int 102:592–606 Kanis JA, Johansson H, Oden A et al (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809–816 Buckley L, Humphrey MB (2018) Glucocorticoid-induced osteoporosis. New Engl J Med 379:2547–2556 Compston J, Cooper A, Cooper C et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43 Briot K, Cortet B, Roux C et al (2014) 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. J Bone Spine 81:493–501 Rizzoli R, Biver E (2015) Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol 11:98 Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045 Allen CS, Yeung JH, Vandermeer B et al (2016) Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev 10:CD001347 Amiche MA, Levesque LE, Gomes T et al (2018) Effectiveness of oral bisphosphonates in reducing fracture risk among oral glucocorticoid users: three matched cohort analyses. J Bone Miner Res 33:419–429 Axelsson KF, Nilsson AG, Wedel H et al (2017) Association between alendronate use and hip fracture risk in older patients using oral prednisolone. JAMA 318:146–155 Bergman J, Nordstrom A, Nordstrom P (2018) Alendronate use and the risk of nonvertebral fracture during glucocorticoid therapy: a retrospective cohort study. J Clin Endocrinol Metab 103:306–313 Saag KG, Wagman RB, Geusens P et al (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6:445–454 Saag KG, Pannacciulli N, Geusens P et al (2019) Denosumab vs risedronate in glucocorticoid-induced osteoporosis: final results of a 24-month randomized, double-blind, double-dummy trial. Arthritis Rheumatol 71:1174–1184 Saag KG, Shane E, Boonen S et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039 Saag KG, Zanchetta JR, Devogelaer JP et al (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346–3355 Karras D, Stoykov I, Lems WF et al (2012) Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study. J Rheumatol 39:600–609 Silverman S, Curtis J, Saag K et al (2015) International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos Int 26:419–420 Van der Goes MC, Jacobs JWG, Boers M et al (2010) Patient and rheumatologist perspectives on glucocorticoids: EULAR recommendations on the management of glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 69:1015–1021 Briot K, Geusens P, Bultink IEM et al (2017) Inflammatory Diseases and bone fragility. Osteoporos Int 28:3301–3314 Raterman H, Bultink IEM, Lems WF (2019) Current treatments and new developments in the management of glucocorticoid-induced osteoporosis. Drugs 79:1065–1087 Weaver CM, Gordon CM, Janz KF et al (2016) The National Osteoporosis Foundation’s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporos Int 27:1281–1386 Briot K, Roux C (2015) Glucocorticoid-induced osteoporosis. RMD Open 1:e000014 Lips P (2007) Relative value of 25(OH)D and 1,25(OH)2D measurements. J Bone Miner Res 22:1668–1671 Gillespie LD, Robertson MC, Gillespie WJ et al (2012) Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007146.pub3 Kanis JA, Johnell O, Oden A et al (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155–162 Maurel DB, Boisseau N, Benhamou CL et al (2012) Alcohol and bone: review of dose effects and mechanisms. Osteoporos Int 23:1–16 Hoes JN, Jacobs JW, Boers M et al (2007) EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66:1560–1567 Black DM, Abrahamsen B, Bouxsein ML et al (2018) Atypical femur fractures—review of epidemiology, relationship to bisphosphonates, prevention and clinical management. Endocr Rev 40:333–368 Raterman HG, de Nijs R, Lems WF (2020) Standpunt van de Nederlandse Vereniging voor Reumatologie inzake Glucocorticoïd-geïnduceerde Osteoporose. GIOP guideline Dutch Society Rheumatology. https://www.nvrnl/wp-content/uploads/2020/01/NVR-Concept-standpunt-GIOPpdf.2020 Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427 Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543 Bliuc D, Alarkawi D, Nguyen TV et al (2015) Risk of subsequent fractures and mortality in elderly women and men with fragility fractures with and without osteoporotic bone density: the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 30:637–646 Gluer CC, Marin F, Ringe JD et al (2013) Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 28:1355–1368 Pepe J, Body JJ, Hadji P et al (2020) Osteoporosis in premenopausal women: a clinical narrative review by the ECTS and the IOF. J Clin Endocrinol Metab 105:2487–2506 Van de Glind EMM, Willems HC, Eslami S et al (2016) Estimating the time to benefit for preventive drugs with the statistical process control method: an example with alendronate. Drugs Aging 33:347–353 Lems WF, Dreinhofer KE, Bischoff-Ferrari H et al (2017) EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures. Ann Rheum Dis 76:802–810 Genant HK, Wu CY, van Kuijk C et al (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148 Kanis JA, Hans D, Cooper C et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411